European seroepidemiology network 2: Standardisation of assays for seroepidemiology of varicella zoster virus.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Ory, Fernando deEchevarría, José Manuel
Kafatos, George
Anastassopoulou, Cleo
Andrews, Nick
Backhouse, Josephine
Berbers, Guy A M
Bruckova, Blazena
Cohen, Daniel I
Melker, Hester E de
Davidkin, Irja
Gabutti, Giovanni
Hesketh, Louise M
Johansen, Kari
Jokinen, Sari
Jones, Lindsay
Linde, Anika
Miller, Elisabeth
Mossong, Joël
Nardone, Anthony
Rota, Maria Cristina
Sauerbrei, Andreas
Schneider, François
Smetana, Zahava
Tischer, Annedore
Tsakris, Athanassios
Vranckx, Robert
Type
ArticleLanguage
en
Metadata
Show full item recordTitle
European seroepidemiology network 2: Standardisation of assays for seroepidemiology of varicella zoster virus.Publiekssamenvatting
BACKGROUND: The aim of the European Sero-Epidemiology Network (ESEN2) is to harmonise the serological surveillance of vaccine-preventable diseases in Europe. OBJECTIVE: To allow comparison of antibody prevalence in different countries by standardising results into common units. STUDY DESIGN: For varicella zoster virus (VZV), a reference laboratory established a panel of 148 samples, characterised by indirect enzyme-immunoassay (ELISA), indirect immunofluorescence, and complement fixation test. Fifty-seven samples were also studied by the fluorescence antibody to membrane antigen test. The geometric mean of the antibody activity (GMAA) obtained from four ELISA determinations was used to characterise each sample of the panel as positive (GMAA: >100 mIU/ml), equivocal (GMAA: 50-100 mIU/ml) or negative (GMAA: <50 mIU/ml) for antibody to VZV (anti-VZV). Thirteen laboratories, using five different ELISA tests, tested the panel. RESULTS: Agreement with the reference laboratory was above 85% in all cases, and the R(2) values obtained from regression analysis of the quantitative results were always higher than 0.87. Finally, the regression equations could be used to convert national values into a common unitage. CONCLUSION: This study confirmed that results for anti-VZV obtained by different ELISA methods can be converted into common units, enabling the comparison of the seroprevalence profiles obtained in the participant countries.PMID
16616612ae974a485f413a2113503eed53cd6c53
10.1016/j.jcv.2006.01.017
Scopus Count
Collections
Related articles
- The European Sero-Epidemiology Network 2 (ESEN2): standardization of assay results for hepatitis A virus (HAV) to enable comparisons of seroprevalence data across 15 countries.
- Authors: Anastassopoulou CG, Kafatos G, Nardone A, Andrews N, Pebody RG, Mossong J, Davidkin I, Gelb D, DE Ory F, Thierfelder W, Nemecek V, Bruzzone B, Butur D, Barbara C, Sobotová Z, Jones L, Griskevicius A, Hesketh LM, Cohen D, Vranckx R, Tsakris A, Miller E, Hatzakis A
- Issue date: 2009 Apr
- Model selection methodology for inter-laboratory standardisation of antibody titres.
- Authors: Kafatos G, Andrews N, Nardone A, ESEN2 project
- Issue date: 2005 Oct 10
- Immunofluorescence test for sensitive detection of varicella-zoster virus-specific IgG: an alternative to fluorescent antibody to membrane antigen test.
- Authors: Sauerbrei A, Färber I, Brandstädt A, Schacke M, Wutzler P
- Issue date: 2004 Jul
- [Seroepidemiology of varicella-zoster virus infection measured by the fluorescent antibody to membrane antigen test].
- Authors: Liu JJ, Wang ML, Gan L, Liao WJ, Chen J
- Issue date: 2009 Apr
- A simplified immunofluorescence technique for antibody to varicella-zoster membrane antigen (FAMA).
- Authors: Baba K, Yoshida M, Tawa A, Yabuuchi H, Maeda K, Takahashi M
- Issue date: 1984 Mar